Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02ZCE
|
||||
| Former ID |
DCL000679
|
||||
| Drug Name |
AD-337
|
||||
| Indication | Fibromyalgia; Myalgia; Chemotherapyinduced emesis [ICD9: 729.1, 787; ICD10:M79.1, M79.7, R11] | Phase 1 | [1] | ||
| Company |
Arakis
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent serotonin transporter | Target Info | Modulator | [2] | |
| KEGG Pathway | Serotonergic synapse | ||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| WikiPathways | Monoamine Transport | ||||
| SIDS Susceptibility Pathways | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| REF 1 | Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.